Abstract
Acyclovir [9-(2-hydroxyethoxymethyl)guanine, ZoviraxTM] is a selective antiviral agent with indications for the treatment of the herpes virus group of injections. In a cross-over design study, three male beagle dogs were given acyclovir i.v. and p.o. (capsule) at 5, 20 and 50 mg/kg doses. Additionally, dogs received acyclovir by gavage at these three doses. After i.v. injection, the acyclovir plasma concentration-time profile, determined by radioimmunoassay, exhibited a biexponential decay with a terminal t1/2 of 2.2 to 3.6 hr. Plasma clearance (3.48-5.83 ml/min/kg) approximated the normal glomerular filtration rate in dogs and the Vd beta (0.97-1.17 liters/kg) indicated distribution of the drug into tissues. Similar kinetic findings were obtained after i.v. administration of [8-14C]acyclovir to dogs. The radioactivity recovered in the urine was 95% of the dose and 92% of the urinary 14C was identified as acyclovir. The remainder of 14C corresponded to minor urinary metabolites. The plasma acyclovir concentration-time curves generated from oral (capsule and gavage) data were fit to a one-compartment open pharmacokinetic model. The half-life and Vd parameters were similar to those calculated for the i.v. route. Peak plasma drug concentrations were reached within 2 hr of dosing. Good oral bioavailability (91 and 80%) was observed after the administration of a capsule at the lower doses (5 and 20 mg/kg, respectively) but bioavailability declined (52%) at the 50 mg/kg dose, indicating the possibility that the gastrointestinal absorption of acyclovir is a saturable process.
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|